2022/01/19
Associate Professor Ruo-Kai Lin’s team/Taipei Medical University
Ruo-Kai Lin, Chin-Sheng Hung, Wei-Wen Hsu, Sheng-Chao Wang, Jung-Ku Liu, Shi-Yun Lin, Mohammad Ansar
The team plans to establish a blood cancer detection company – EG BioMed Co., Ltd., which is committed to the application of plasma cell-free DNA methylation detection technology to develop detection services and reagent groups for early detection of cancer, treatment monitoring and recurrence prediction The product is commercialized with early breast cancer detection as the primary indication and intended use, and it is expected to authorize the technology to strategic cooperative manufacturers in various countries to quickly deploy the global blood cancer detection market.
Review recommendation
1. Apply plasma free DNA methylation detection technology to develop a detection service and reagent group products for early detection of cancer, treatment monitoring and recurrence prediction, only need to draw blood, and do not need to do other invasive detection methods, which is innovative.
2. The research results were published in Cancers. At present, Shuang-He Hospital has set up self-funded testing, and entrusted GBC company to produce testing reagent kits, and has planned to establish a new company.
3. In the future, it plans to benefit from reagent sales and technology authorization. Has applied for invention patents in 8 countries and regions including the United States, the European Union, Australia, Mainland China, Japan, South Korea, Singapore and Malaysia.
4. Whole-genome body methylation analysis can be applied not only to breast cancer, but also to colorectal cancer, pancreatic cancer, etc., with high development potential.